Development | Vaccine | Anti-Aging Vaccine
Anti-Aging Vaccine
Development of a Senolytic Vaccine for Selective Elimination of Senescent Cells Using Tissue-Specific Target Antigens.
The progression of age-related diseases is known to be associated with the accumulation of senescent cells in various tissues and organs. Recent studies have demonstrated the beneficial effects of senolytic compounds that selectively induce apoptosis in these cells. However, current senolytics suffer from low specificity, potential side effects, and limited efficacy.
Vaccine-based approaches for preventing or treating age-related conditions offer promising opportunities to extend healthy lifespan and have significant economic potential. Research shows that clearing senescent cells leads to tissue regeneration, rejuvenation, and extended lifespan in animal models.
While cytotoxic antibodies and CAR-T therapies have shown relatively high specificity and effectiveness in mouse studies, their widespread application is hindered by extremely high costs, complex manufacturing, and logistical challenges. In contrast, senolytic vaccines present a more viable solution.
We have developed a composite vaccine antigen incorporating tissue-specific targets for precise elimination of senescent cells. The antigen includes carefully selected immunogenic epitopes from human protein targets, recognizable by cytotoxic and helper T-lymphocytes. These epitopes show sufficient conservation to allow evaluation in mouse models.
ASenolytic Targets in the Vaccine Antigen:
CD153 (TNFRSF8) - Targets aging-associated T-cells in adipose tissue and germinal centers. CD153 vaccination reduces senescent T-cells in fat tissue, improves glucose tolerance, and enhances insulin sensitivity.
GPNMB - Targets senescent endothelial cells, adipocytes, and leukocytes. Immunization against GPNMB improves metabolic parameters, glucose tolerance, and reduces atherosclerotic plaques.
CD87 - Поверхностный рецептор активатора плазминогена урокиназы.
Мишень - Широкий спектр стареющих клеток.
Элиминация клеток, несущих CD87, улучшает физическую работоспособность при физиологическом старении и снижает метаболическую дисфункцию.
CD87 (uPAR) - Broadly targets various senescent cell types. Eliminating CD87-positive cells enhances physical performance during aging and reduces metabolic dysfunction.
CD9 - Targets senescent endothelial cells. This tetraspanin represents a novel target for preventing vascular aging and atherosclerosis, making it potentially valuable for senolytic vaccines.
KLRG1 - Targets senescent T-cells and NK cells. As a marker of immune aging, clearing KLRG1-positive cells leads to lasting immune system rejuvenation.
The antigenic epitopes are connected by hybrid linkers, and the vaccine includes an intramolecular adjuvant to enhance immunogenicity. The primary goal of this senotherapy is to safely mitigate aging effects and extend healthspan.
Anti-Aging Vaccine
Development of a Senolytic Vaccine for Selective Elimination of Senescent Cells Using Tissue-Specific Target Antigens.
The progression of age-related diseases is known to be associated with the accumulation of senescent cells in various tissues and organs. Recent studies have demonstrated the beneficial effects of senolytic compounds that selectively induce apoptosis in these cells. However, current senolytics suffer from low specificity, potential side effects, and limited efficacy.
Vaccine-based approaches for preventing or treating age-related conditions offer promising opportunities to extend healthy lifespan and have significant economic potential. Research shows that clearing senescent cells leads to tissue regeneration, rejuvenation, and extended lifespan in animal models.
While cytotoxic antibodies and CAR-T therapies have shown relatively high specificity and effectiveness in mouse studies, their widespread application is hindered by extremely high costs, complex manufacturing, and logistical challenges. In contrast, senolytic vaccines present a more viable solution.
We have developed a composite vaccine antigen incorporating tissue-specific targets for precise elimination of senescent cells. The antigen includes carefully selected immunogenic epitopes from human protein targets, recognizable by cytotoxic and helper T-lymphocytes. These epitopes show sufficient conservation to allow evaluation in mouse models.
ASenolytic Targets in the Vaccine Antigen:
CD153 (TNFRSF8) - Targets aging-associated T-cells in adipose tissue and germinal centers. CD153 vaccination reduces senescent T-cells in fat tissue, improves glucose tolerance, and enhances insulin sensitivity.
GPNMB - Targets senescent endothelial cells, adipocytes, and leukocytes. Immunization against GPNMB improves metabolic parameters, glucose tolerance, and reduces atherosclerotic plaques.
CD87 - Поверхностный рецептор активатора плазминогена урокиназы.
Мишень - Широкий спектр стареющих клеток.
Элиминация клеток, несущих CD87, улучшает физическую работоспособность при физиологическом старении и снижает метаболическую дисфункцию.
CD87 (uPAR) - Broadly targets various senescent cell types. Eliminating CD87-positive cells enhances physical performance during aging and reduces metabolic dysfunction.
CD9 - Targets senescent endothelial cells. This tetraspanin represents a novel target for preventing vascular aging and atherosclerosis, making it potentially valuable for senolytic vaccines.
KLRG1 - Targets senescent T-cells and NK cells. As a marker of immune aging, clearing KLRG1-positive cells leads to lasting immune system rejuvenation.
The antigenic epitopes are connected by hybrid linkers, and the vaccine includes an intramolecular adjuvant to enhance immunogenicity. The primary goal of this senotherapy is to safely mitigate aging effects and extend healthspan.
Eurasian Invention Application No. 202591260 - "Anti-Aging Vaccine"
Patent Application
Leave your request, and we will contact you.
Would you like us to develop a custom drug?
Сообщение об успешной отправке!
Phone:
Email:
